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Background
Published literature indicates racial/ethnic minorities are
underrepresented in clinical trials when compared to
white/non-Hispanics. Enrollment of diverse populations
is important because minorities have disproportionately
higher rates of HIV infection. This analysis evaluates the
enrollment process for minorities compared to whites at
the Vaccine Research Center (VRC) Clinical Trials Core
(CTC) among healthy HIV-uninfected volunteer into HIV
vaccine studies in metropolitan Washington, DC.
Methods
Demographic and medical data were collected to deter-
mine volunteer eligibility for in-person clinical screen.
Consented volunteers underwent laboratory evaluation
and physical exam. Eligible subjects were consented again
for enrollment into vaccine trials.
Results
Of n = 304 individuals prescreened in 2009 for HIV-1 vac-
cine clinical trials, n = 66 (22%) progressed to clinical
screen; and n = 17 (6%) enrolled in a vaccination proto-
col; at each stage, 61%, 41%, and 29% were minorities,
respectively. Minorities were more likely to be unable to
enroll due to protocol ineligibility (65%) or discontinued
screening (70%) compared to their white counterparts;
35% and 30% respectively.
Conclusion
Minorities comprise 68% of prescreening volunteers indi-
cating significant interest in the minority community for
participating in phase I HIV vaccine studies. However,
minority volunteers have a greater chance of enrollment
ineligibility than their white counterparts, and more often
decide not to participate during the enrollment process.
This suggests health care disparities based on race impact
access to clinical research opportunities, and that greater
efforts are needed in community outreach and education,
access to health care, and trust-building to assure partici-
pation and enrollment of diverse populations in HIV vac-
cine trials.
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